Evidence map›Paper›PMID 37762691›Full record

ArticleInternational journal of molecular sciences2023

Evaluating the Utility of ctDNA in Detecting Residual Cancer and Predicting Recurrence in Patients with Serous Ovarian Cancer.

Jie Wei Zhu, Fabian Wong, Agata Szymiczek, Gabrielle E V Ene, Shiyu Zhang, Taymaa May, Steven A Narod, Joanne Kotsopoulos, Mohammad R Akbari

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Ovarian Cancer Diagnosis and Prognosis Based on Cell-Free DNA Methylation.Cancer control : journal of the Moffitt Cancer Center
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jie Wei ZhuWomen's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON M5S 1B2, Canada.ORCID 0000-0001-7251-8114
Fabian WongWomen's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON M5S 1B2, Canada.ORCID 0000-0002-5586-9622
Agata SzymiczekWomen's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON M5S 1B2, Canada.
Gabrielle E V EneDivision of Gynecologic Oncology, Department of Surgical Oncology, Princess Margaret Cancer Center, University Health Network, Toronto, ON M5G 2M9, Canada.
Shiyu ZhangWomen's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON M5S 1B2, Canada.
Taymaa MayDivision of Gynecologic Oncology, Department of Surgical Oncology, Princess Margaret Cancer Center, University Health Network, Toronto, ON M5G 2M9, Canada.
Steven A NarodWomen's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON M5S 1B2, Canada.ORCID 0000-0001-5798-0626
Joanne KotsopoulosWomen's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON M5S 1B2, Canada.
Mohammad R AkbariWomen's College Research Institute, Women's College Hospital, University of Toronto, Toronto, ON M5S 1B2, Canada.
University of Toronto · CAUniversity Health Network · CA

Funding

Canadian Institute of Health Research 365684
6 · The paper itself

Abstract

Ovarian cancer has a high case fatality rate, but patients who have no visible residual disease after surgery have a relatively good prognosis. The presence of any cancer cells left in the peritoneal cavity after treatment may precipitate a cancer recurrence. In many cases, these cells are occult and are not visible to the surgeon. Analysis of circulating tumour DNA in the blood (ctDNA) may offer a sensitive method to predict the presence of occult (non-visible) residual disease after surgery and may help predict disease recurrence. We assessed 48 women diagnosed with serous ovarian cancer (47 high-grade and 1 low-grade) for visible residual disease and for ctDNA. Plasma, formalin-fixed paraffin-embedded (FFPE) tumour tissue and white blood cells were used to extract circulating free DNA (cfDNA), tumour DNA and germline DNA, respectively. We sequenced DNA samples for 59 breast and ovarian cancer driver genes. The plasma sample was collected after surgery and before initiating chemotherapy. We compared survival in women with no residual disease, with and without a positive plasma ctDNA test. We found tumour-specific variants (TSVs) in cancer cells from 47 patients, and these variants were sought in ctDNA in their post-surgery plasma. Fifteen (31.9%) of the 47 patients had visible residual disease; of these, all 15 had detectable ctDNA. Thirty-one patients (65.9%) had no visible residual disease; of these, 24 (77.4%) patients had detectable ctDNA. Of the patients with no visible residual disease, those patients with detectable ctDNA had higher mortality (20 of 27 died) than those without detectable ctDNA (3 of 7 died) (HR 2.32; 95% CI: 0.67-8.05), although this difference was not statistically significant (

Indexed as

Cell-Free Nucleic AcidsCystadenocarcinoma, SerousOvarian NeoplasmsCarcinoma, Ovarian EpithelialFemaleHumansNeoplasm Recurrence, LocalNeoplasm, ResidualOncogenesCell-Free Nucleic Acidscirculating tumour DNAliquid biopsyminimal residual diseaseovarian cancerprognosis

Identifiers

PMID37762691
PMCPMC10532395
OpenAlexW4386913763

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.